vs
Side-by-side financial comparison of INNOSPEC INC. (IOSP) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
INNOSPEC INC. is the larger business by last-quarter revenue ($453.2M vs $250.2M, roughly 1.8× USANA HEALTH SCIENCES INC). INNOSPEC INC. runs the higher net margin — 6.8% vs 3.0%, a 3.8% gap on every dollar of revenue. On growth, INNOSPEC INC. posted the faster year-over-year revenue change (2.8% vs -3.0%). Over the past eight quarters, USANA HEALTH SCIENCES INC's revenue compounded faster (11.8% CAGR vs 2.1%).
Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is an American specialty chemical company. It comprises three business units:The Performance Chemicals business trades in the personal care, home care, agrochemical, mining and industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives. The Oilfield Services business supplies drilling, completion and production chemicals.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
IOSP vs USNA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $453.2M | $250.2M |
| Net Profit | $30.8M | $7.5M |
| Gross Margin | 27.3% | 76.2% |
| Operating Margin | 8.1% | 5.5% |
| Net Margin | 6.8% | 3.0% |
| Revenue YoY | 2.8% | -3.0% |
| Net Profit YoY | -8.3% | -20.0% |
| EPS (diluted) | $1.22 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $453.2M | $250.2M | ||
| Q4 25 | $455.6M | $226.2M | ||
| Q3 25 | $441.9M | $213.7M | ||
| Q2 25 | $439.7M | $235.8M | ||
| Q1 25 | $440.8M | $249.5M | ||
| Q4 24 | $466.8M | $213.6M | ||
| Q3 24 | $443.4M | $200.2M | ||
| Q2 24 | $435.0M | — |
| Q1 26 | $30.8M | $7.5M | ||
| Q4 25 | $47.4M | $180.0K | ||
| Q3 25 | $12.9M | $-6.5M | ||
| Q2 25 | $23.5M | $9.7M | ||
| Q1 25 | $32.8M | $9.4M | ||
| Q4 24 | $-70.4M | $4.5M | ||
| Q3 24 | $33.4M | $10.6M | ||
| Q2 24 | $31.2M | — |
| Q1 26 | 27.3% | 76.2% | ||
| Q4 25 | 28.0% | 78.2% | ||
| Q3 25 | 26.4% | 77.2% | ||
| Q2 25 | 28.0% | 78.7% | ||
| Q1 25 | 28.4% | 79.0% | ||
| Q4 24 | 29.2% | 82.0% | ||
| Q3 24 | 28.0% | 80.4% | ||
| Q2 24 | 29.2% | — |
| Q1 26 | 8.1% | 5.5% | ||
| Q4 25 | 10.3% | 1.7% | ||
| Q3 25 | 1.3% | 0.6% | ||
| Q2 25 | 7.8% | 7.1% | ||
| Q1 25 | 9.6% | 6.3% | ||
| Q4 24 | 8.8% | 3.8% | ||
| Q3 24 | 10.3% | 7.8% | ||
| Q2 24 | 9.4% | — |
| Q1 26 | 6.8% | 3.0% | ||
| Q4 25 | 10.4% | 0.1% | ||
| Q3 25 | 2.9% | -3.1% | ||
| Q2 25 | 5.3% | 4.1% | ||
| Q1 25 | 7.4% | 3.8% | ||
| Q4 24 | -15.1% | 2.1% | ||
| Q3 24 | 7.5% | 5.3% | ||
| Q2 24 | 7.2% | — |
| Q1 26 | $1.22 | $0.41 | ||
| Q4 25 | $1.90 | $-0.10 | ||
| Q3 25 | $0.52 | $-0.36 | ||
| Q2 25 | $0.94 | $0.52 | ||
| Q1 25 | $1.31 | $0.49 | ||
| Q4 24 | $-2.80 | $0.23 | ||
| Q3 24 | $1.33 | $0.56 | ||
| Q2 24 | $1.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $289.1M | $162.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | — |
| Total Assets | $1.8B | $739.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $289.1M | $162.8M | ||
| Q4 25 | $292.5M | $158.4M | ||
| Q3 25 | $270.8M | $145.3M | ||
| Q2 25 | $266.6M | $151.3M | ||
| Q1 25 | $299.8M | $179.6M | ||
| Q4 24 | $289.2M | $181.8M | ||
| Q3 24 | $303.8M | $364.9M | ||
| Q2 24 | $240.2M | — |
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $528.1M | ||
| Q2 25 | $1.3B | $531.1M | ||
| Q1 25 | $1.3B | $529.8M | ||
| Q4 24 | $1.2B | $532.1M | ||
| Q3 24 | $1.2B | $533.1M | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $1.8B | $739.0M | ||
| Q4 25 | $1.8B | $742.9M | ||
| Q3 25 | $1.8B | $726.6M | ||
| Q2 25 | $1.8B | $734.5M | ||
| Q1 25 | $1.8B | $746.6M | ||
| Q4 24 | $1.7B | $748.2M | ||
| Q3 24 | $1.8B | $671.3M | ||
| Q2 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 0.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $17.6M | — | ||
| Q4 25 | $61.4M | — | ||
| Q3 25 | $39.3M | $-2.0M | ||
| Q2 25 | $9.3M | $12.2M | ||
| Q1 25 | $28.3M | $15.5M | ||
| Q4 24 | $25.7M | $5.8M | ||
| Q3 24 | $73.5M | $29.5M | ||
| Q2 24 | $4.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $46.8M | — | ||
| Q3 25 | $25.0M | $-5.2M | ||
| Q2 25 | $-3.7M | $7.2M | ||
| Q1 25 | $19.9M | $12.7M | ||
| Q4 24 | $13.6M | $4.0M | ||
| Q3 24 | $65.8M | $27.1M | ||
| Q2 24 | $-6.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.3% | — | ||
| Q3 25 | 5.7% | -2.4% | ||
| Q2 25 | -0.8% | 3.0% | ||
| Q1 25 | 4.5% | 5.1% | ||
| Q4 24 | 2.9% | 1.9% | ||
| Q3 24 | 14.8% | 13.6% | ||
| Q2 24 | -1.4% | — |
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.2% | — | ||
| Q3 25 | 3.2% | 1.5% | ||
| Q2 25 | 3.0% | 2.1% | ||
| Q1 25 | 1.9% | 1.1% | ||
| Q4 24 | 2.6% | 0.8% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 2.5% | — |
| Q1 26 | 0.57× | — | ||
| Q4 25 | 1.30× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 0.40× | 1.27× | ||
| Q1 25 | 0.86× | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | 2.20× | 2.78× | ||
| Q2 24 | 0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
